Clinical observation of gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients
10.3760/cma.j.issn.1673-4904.2014.17.020
- VernacularTitle:替吉奥联合奥沙利铂治疗晚期胃癌临床研究
- Author:
Zhiping SHAO
;
Xiaoqu HU
;
Jicheng LI
- Publication Type:Journal Article
- Keywords:
Gimeracil and oteracil potassium;
Oxaliplatin;
Advanced gastric carcinom
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(17):56-59
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the curative effect and clinical safety of gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients.Methods From January 2009 to December 2011,116 cases with advanced gastric carcinoma were randomly chosen and divided into group A,B (58 cases in each group).Group A was given gimeracil and oteracil potassium combined with oxaliplatin,while group B was given oxaliplatin,fluorouracil and calcium folinate.Before and after dosing,the blood routine,liver and kidney function,chest CT scanning and gastroscope inspection were observed,the recent curative effect and adverse reaction of chemotherapy were analyzed.The patients' survival time and disease progression were compared.Results The curative effect of 116 patients could all be evaluated,and the effective rate of group A and group B were 48.3％(28/58) and 29.3％(17/58),while clinical benefit rate were 74.1％(43/58) and 55.2％(32/58),there was significant difference(P ＜ 0.05).The survival rate of two groups at different time points had no significant difference (P ＞0.05).The rate of nauseated and vomiting were 34.5％(20/58),37.9％(22/58) in group A,and 67.2％(39/58),62.1％(36/58) in group B,there was significant difference (P ＜ 0.05).The influence of drugs on blood system,common peripheral neurotoxicity,extremities syndrome and inflammation of the oral mucosa between two groups had no significant difference (P ＞0.05).Conclusions Gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients has better clinical effect and less complication,which is worthy of further promotion.
